Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa
Abstract We report in vivo development of cefiderocol (FDC) resistance among four sequential Pseudomonas aeruginosa clinical isolates ST244 recovered from a single patient, without exposure to FDC, which raises concern about the effectiveness of this novel drug. The first recovered P. aeruginosa isolate (P-01) was susceptible to FDC (2 μg/mL), albeit this MIC value was higher than that of a wild-type P. aeruginosa (0.12–0.25 μg/ml). The subsequent isolated strains (P-02, P-03, P-04) displayed increasing levels of FDC MICs (8, 16, and 64 μg/ml, respectively). Those isolates also showed variable and gradual increasing levels of resistance to most β-lactams tested in this study. Surprisingly, no acquired β-lactamase was identified in any of those isolates. Whole-genome sequence analysis suggested that this resistance was driven by multifactorial mechanisms including mutational changes in iron transporter proteins associated with FDC uptake, ampC gene overproduction, and mexAB-oprM overexpression. These findings highlight that a susceptibility testing to FDC must be performed prior to any prescription..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
European journal of clinical microbiology & infectious diseases - 42(2022), 1 vom: 15. Nov., Seite 61-66 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sadek, Mustafa [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s10096-022-04526-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR048993891 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR048993891 | ||
| 003 | DE-627 | ||
| 005 | 20230519071343.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230106s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10096-022-04526-0 |2 doi | |
| 035 | |a (DE-627)SPR048993891 | ||
| 035 | |a (SPR)s10096-022-04526-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sadek, Mustafa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Abstract We report in vivo development of cefiderocol (FDC) resistance among four sequential Pseudomonas aeruginosa clinical isolates ST244 recovered from a single patient, without exposure to FDC, which raises concern about the effectiveness of this novel drug. The first recovered P. aeruginosa isolate (P-01) was susceptible to FDC (2 μg/mL), albeit this MIC value was higher than that of a wild-type P. aeruginosa (0.12–0.25 μg/ml). The subsequent isolated strains (P-02, P-03, P-04) displayed increasing levels of FDC MICs (8, 16, and 64 μg/ml, respectively). Those isolates also showed variable and gradual increasing levels of resistance to most β-lactams tested in this study. Surprisingly, no acquired β-lactamase was identified in any of those isolates. Whole-genome sequence analysis suggested that this resistance was driven by multifactorial mechanisms including mutational changes in iron transporter proteins associated with FDC uptake, ampC gene overproduction, and mexAB-oprM overexpression. These findings highlight that a susceptibility testing to FDC must be performed prior to any prescription. | ||
| 650 | 4 | |a Cefiderocol |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Iron transporters |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a In vivo |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Le Guern, Rémi |4 aut | |
| 700 | 1 | |a Kipnis, Eric |4 aut | |
| 700 | 1 | |a Gosset, Philippe |4 aut | |
| 700 | 1 | |a Poirel, Laurent |0 (orcid)0000-0001-5160-5286 |4 aut | |
| 700 | 1 | |a Dessein, Rodrigue |4 aut | |
| 700 | 1 | |a Nordmann, Patrice |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical microbiology & infectious diseases |d Berlin : Springer, 1982 |g 42(2022), 1 vom: 15. Nov., Seite 61-66 |w (DE-627)SPR008661995 |w (DE-600)1459049-9 |x 1435-4373 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:1 |g day:15 |g month:11 |g pages:61-66 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10096-022-04526-0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 1 |b 15 |c 11 |h 61-66 | ||